NOVEL METHOD FOR QUANTIFYING HEPATIC STEATOSIS IN PATIENTS WITH METABOLICALLY ASSOCIATED FATTY LIVER DISEASE

Introduction. The article presents an overview of novel complex algorithm based on methods of ultrasound steatometry, combined elastography and dual-energy X-ray absorbtiometry in “Whole body” mode in diagnostic and monitoring of metabolically associated fatty liver disease.

The purpose of the study: to assess the possibility of quantitative ultrasound steatometry using in the detection and monitoring of metabolically associated fatty liver disease.

Material and methods. 157 patients were examined. The main group consisted of 47 patients with liver steatosis; 45 patients with steatohepatitis and clinically insignificant liver fibrosis (F0-F1); 32 patients with steatohepatitis and clinically significant liver fibrosis (F2-F3); 33 patients with focal hepatic steatosis. We used complex algorithm based on methods of questionnaires, laboratory tests, ultrasound steatometry, combined elastography and dual-energy x-ray absorbtiometry in “Whole body” mode, liver biopsy. to determine the severity of steatosis, a scale was used: S0 – no steatosis; 2.9 dB/cm.

Results and conclusion. It is possible to use quantitative ultrasound steatometry for metabolically associated fatty liver disease, as a reference method both for the initial detection of the disease and for monitoring non-drug treatment (sensitivity 90.7%, specificity 92.4%). The optimal complex for the diagnosis and monitoring of non-drug treatment of metabolically associated fatty liver disease includes an assessment of the level of compliance, the use of quantitative ultrasound steatometry and dual-energy X-ray absorptiometry in the «Whole body» mode (sensitivity 92.8%, specificity 92.3%).